Funded by the European and Developing Clinical Trials Partnership and sponsored by St George’s, University of London, PREPARE aims to define and reduce the burden of neonatal, infant and maternal GBS in a Sub-Saharan African population The programme of work also seeks to estimate the level of antibodies for protection against major GBS types causing disease across European and African sites.
Group B Streptococcus (GBS) is a leading cause of neonatal infection in Europe, and increasingly recognised as a significant cause of neonatal infection in Sub-Saharan Africa.
Over 319,000 infant cases are estimated to occur globally each year. GBS also accounts for 33,000 cases of disease in pregnant or post-partum women, 57,000 stillbirths and 90,000 infant deaths - more than the total number of deaths from mother-to child transmission of HIV and more than the combined neonatal deaths from tetanusand pertussis.
Long term control of GBS depends on the availability of an effective vaccine. A GBS vaccine would reduce the burden of GBS (maternal disease, stillbirths, premature births and infant disease) by protecting both mothers and infants. Several vaccine candidates are currently in development.
We aim to build capacity in Uganda for future vaccine studies. We will work with experts from other countries that have undertaken vaccine studies in pregnant women. This will help us when considering regulatory and ethical issues in preparation for clinical trials in this population.